The Role of m6A Modification and m6A Regulators in Esophageal Cancer

Simple Summary N6-methyladenosine (m6A) modification and m6A regulators play important roles in the occurrence and development of various cancers. Esophageal cancer (ESCA), one of the most common gastrointestinal tumors, seriously affects people’s health. In this review article, we summarized the role and possible mechanism of m6A modification and m6A regulators in the occurrence, progression, remedy and prognosis of ESCA, which might be useful for determining the pathogenesis of ESCA and providing direction for the future research of ESCA. Abstract N6-methyladenosine (m6A) modification, the most prevalent RNA modification, is involved in all aspects of RNA metabolism, including RNA processing, nuclear export, stability, translation and degradation. Therefore, m6A modification can participate in various physiological functions, such as tissue development, heat shock response, DNA damage response, circadian clock control and even in carcinogenesis through regulating the expression or structure of the gene. The deposition, removal and recognition of m6A are carried out by methyltransferases, demethylases and m6A RNA binding proteins, respectively. Aberrant m6A modification and the dysregulation of m6A regulators play critical roles in the occurrence and development of various cancers. The pathogenesis of esophageal cancer (ESCA) remains unclear and the five-year survival rate of advanced ESCA patients is still dismal. Here, we systematically reviewed the recent studies of m6A modification and m6A regulators in ESCA and comprehensively analyzed the role and possible mechanism of m6A modification and m6A regulators in the occurrence, progression, remedy and prognosis of ESCA. Defining the effect of m6A modification and m6A regulators in ESCA might be helpful for determining the pathogenesis of ESCA and providing some ideas for an early diagnosis, individualized treatment and improved prognosis of ESCA patients.


Introduction
N 6 -methyladenosine (m 6 A) refers to the methylation at the N 6 position of adenosine, which is considered to be the most prevalent RNA modification. Approximately one to two m 6 A residues are found in every 1000 nucleotides [1,2], and are mainly located in the RRACH sequence (R = A or G, H = A, C, or U) [3,4]. However, not all RRACH motifs are methylated, which suggests that methylation at the N 6 position of adenosine is specific and selective [5,6]. N 6 -methyladenosine occurs in mRNA, rRNA, long non-coding RNA (lncRNA), microRNA (miRNA), circular RNA (circRNA), etc., and is involved in all aspects of RNA metabolism, including RNA processing, nuclear export, stability, translation and addition to the catalytic core of MTC, other components are associated with WTAP and are helpful for the recruitment and localization of the METTL3-METTL14 heterodimer [35][36][37][38][39]. In a WTAP-dependent manner, RBM15/RBM15B correlates with METTL3 and recruits MTC to U-rich regions immediately adjacent to RRACH motifs to catalyze the deposition of m 6 A [37,40,41]. VIRMA is also a WTAP-associated factor and recruits MTC to 3 -UTR and near the stop codon for m 6 A catalysis [39]. ZC3H13 connects RBM15/RBM15B with WTAP through its C-terminal structure domain [36,38]. The knockdown of ZC3H13 leads to translocation from the nucleus to cytoplasm for a large proportion of WTAP, VIRMA, HAKAI, METTL3 and METTL14, indicating the important role of ZC3H13 for the nuclear localization of MTC [38]. HAKAI is an E3 ubiquitin-protein ligase, while its role in m 6 A catalysis is unclear. It is worth noting that m 6 A deposition depends on transcription. METTL3 and METTL14 form a heterodimer in the cytoplasm and then the heterodimer enters the nucleus with the help of a nuclear localization signal in METTL3. METTL4 can recognize and bind to histone H3 trimethylation at Lys36 (H3k36me3), promote the binding of MTC with RNA polymerase II and transfer MTC to actively transcribing RNAs to install m 6 A cotranscriptionally [42].
In addition to MTC, there are other methyltransferases, such as methyltransferase-like protein 16 (METTL16), cap-specific adenosine methyltransferase (CAPAM), methyltransferaselike protein 5 (METTL5)/tRNA methyltransferase activator subunit 11-2 (TRMT112) complex and zinc finger CCHC-type containing 4 (ZCCHC4). METTL16 catalyzes m 6 A deposition in the A43 of U6 small nuclear RNA (snRNA), and is involved in the splicing of RNA [43,44]. The m 6 A 43 is considered to affect the interaction between snRNA and pre-mRNA and thus regulate the splicing of pre-mRNA [44]. Methionine adenosyl transferase 2A (MAT2A) encodes SAM synthetase. The 3 -UTR hairpins of MAT2A mRNA are substrates of METTL16. The m 6 A modification of 3 -UTR hairpins influences the splicing of MAT2A pre-mRNA and maintains SAM homeostasis [43,45]. If 2 -O-methyladenosine (Am) is the first transcribed nucleotide of eukaryotic capped mRNAs, CAPAM can recognize it and deposit m 6 A on it to form a m 7 GPPPm 6 Am motif [46,47]. The METTL5/TRMT112 complex and ZCCHC4 are responsible for the methylation of the A1832 of 18S and A4220 of 28S rRNA, respectively [48][49][50].

Demethylases
Demethylases are termed as "erasers". The m 6 A demethylation occurs on nascent transcripts. FTO is the first identified demethylase, and alkB homolog 5 (ALKBH5) is the second one. Ferrous iron and α-ketoglutarate are cofactors of FTO and ALKBH5 [51]. Both FTO and ALKBH5 can remove m 6 A modification on single RNA and DNA [8,52]. In addition, FTO also can act as demethylase for N 6 ,-2 -O-dimethyladenosine (m 6 Am) near the N 7 -methylguanosine (m 7 G) cap [53].

m 6 A RNA Binding Proteins
The fate of m 6 A-modified RNA depends on the protein that binds to it. This kind of RNA binding protein is referred to as a "reader". Readers include YT521-B homology (YTH) family proteins, insulin like growth factor 2 mRNA binding proteins (IGF2BPs), heterogeneous nuclear ribonucleoproteins (HNRNPs) and eukaryotic translation initiation factor 3 (EIF3).

m 6 A Modification and Its Effect on Various RNAs in ESCA
A proper m 6 A level, mainly relying on the appropriate expression and function of m 6 A regulators, is necessary for sustaining normal bioprocesses. The disruption of the dynamic balance between the installation and removal of m 6 A modification will lead to the development of diseases, including cancer. An aberrant m 6 A level associated with the dysregulation of m 6 A regulators has been reported in a variety of cancers, such as gastric cancer, hepatocellular carcinoma, bladder cancer, etc. [54][55][56]. Nucleotide sequence changes could also result in the gain or loss of m 6 A sites and contribute to carcinogenesis [57,58].
For example, a base transition from the G to A of rs5746136 in SOD2 led to an increased m 6 A modification level of SOD2 and an increased binding of HNRNPC with SOD2 through an "m 6 A switch" mechanism followed by the upregulation of SOD2. The overexpression of SOD2 inhibited the proliferation, migration and invasion of bladder cancer cells, which suggested that SOD2 acted as a tumor suppressor gene for bladder cancer. Thus, the A allele of rs5746136 in SOD2 was associated with a reduced risk of bladder cancer [57]. m 6 A could deposit on various type of RNA, such as coding RNA and non-coding RNA, participate in all steps of RNA metabolism and post-transcriptionally regulate the expression of the gene (Table 1)  .

m 6 A Modification in ESCA
Most studies revealed that the m 6 A level was elevated in ESCC tissues and cell lines [73,[84][85][86]. However, Cui et al. [83] found lower m 6 A levels in ESCC cell lines and tissues compared to their counterparts. Some studies indicated that the m 6 A level could act as a diagnostic and prognostic marker. In gastric cancer, the m 6 A level might be used to distinguish patients from healthy individuals and predict the prognosis of patients treated with immunotherapy [87,88]. In lung cancer, a higher m 6 A level in circulating tumor cells than in whole blood cells might be associated with tumor metastasis [89]. Inconsistent results of the m 6 A level in ESCC suggested that further large sample studies are needed to draw a reliable conclusion.

The Effect of m 6 A Modification on mRNA in ESCA
The fate of m 6 A-modified RNA relies on the m 6 A reader that binds to it. YTH family proteins, consisting of YTH m 6 A-binding protein 1 (YTHDF1), YTHDF2, YTHDF3, YTH domain-containing 1 (YTHDC1) and YTHDC2, contain a specific YTH domain, through which, they can recognize and bind to target RNA in an m 6 A-dependent way [90,91]. YTHDF1 promotes translation initiation and protein synthesis [10]. On the contrary, YTHDF2, the first discovered m 6 A reader, enhances the degradation of m 6 A-modified mRNA, either by delivering them to the mRNA decay site or recruiting the CCR4-NOT deadenylase complex to initiate mRNA degradation [9,92]. YTHDF3 interacts with YTHDF1 or YTHDF2, playing opposite roles by promoting mRNA translation or enhancing mRNA degradation [93,94]. YTHDC1 regulates the splicing of the exon and promotes the translocation of m 6 A-modified mRNA from the nucleus to the cytoplasm [95][96][97]. YTHDC2 elevates the translation efficiency of m 6 A-modified mRNA; accordingly, the abundance of target mRNA is reduced [98,99]. IGF2BPs, including IGF2BP1, IGF2BP2 and IGF2BP3, enhance mRNA stability [100]. HNRNPs contain HNRNPA2B1, HNRNPC and HNRNPG. HNRNPC and HNRNPG regulate the alternative splicing of mRNA in an m 6 A-dependent way [13,101]. EIF3 can act as reader of m 6 A in the 5 -UTR of mRNA [17]. EIF3 participates in almost all steps of translation initiation, which is a rate-limiting process. EIF3 promotes the formation of the 43S pre-initiation complex (PIC), bridges 43S PIC and mRNA bound to the EIF4F complex and takes part in the AUG start codon scanning process [102][103][104][105].
It is generally acknowledged that YTHDF1 plays a facilitating role in translation initiation and protein synthesis [10]. That was true in the study from Zhao et al. [73], which demonstrated that YTHDF1 upregulated the protein level of ERBB2 through recognizing m 6 A-modified ERBB2 mRNA. Conversely, the knockdown of YTHDF1 enhanced the protein level of HSD17B11, which suggested that YTHDF1 decreased the translation efficiency of m 6 A-modified HSD17B11 mRNA [74]. YTHDF2 promoted the degradation of APC mRNA and decreased APC expression via binding to m 6 A-modified APC mRNA [69]. IGF2BP2 enhanced the stability of m 6 A-modified TK1 and KIF18A mRNA and upregulated their expression [66]. In addition, m 6 A readers could regulate the stability and expression of their downstream mRNAs through interacting with lncRNA [63][64][65]68,70]. For example, LBX2-AS1 and HNRNPC synergized to increase the stability of ZEB1 and ZEB2 mRNA, upregulated their expression and consequently promoted the migration and epithelial mesenchymal transition (EMT) of ESCC cells [68].

The Effect of m 6 A Modification on Non-Coding RNAs in ESCA
Although without a coding ability, non-coding RNAs (ncRNAs), such as miRNA, lncRNA and circRNA, serve a critical role in regulating the expression of the gene.
The miRNAs bind to the 3 -UTR of the target mRNA, and then silence or inhibit the expression of corresponding genes. miRNA biogenesis includes the following steps: firstly, primary miRNA (pri-miRNA) is transcribed from DNA; secondly, pri-miRNA is cleaved into precursor miRNA (pre-miRNA), which requires a microprocessor complex composed of drosha ribonuclease III (DROSHA) and DiGeorge syndrome critical region 8 (DGCR8); thirdly, pre-miRNA is cleaved into mature miRNA. In ESCC, m 6 A writers and erasers deposit and remove m 6 A on pri-miRNA, respectively [75,[77][78][79]. For instance, METTL3 elevates the m 6 A level of pri-miR-200-5p, whereas ALKBH5 reduces the m 6 A level of pri-miR-194-2 [75,78]. A previous study showed that HNRNPA2B1 played a crucial role in the maturation of miRNA through recognizing m 6 A on pri-miRNA and interacting with DROSHA and DDGCR8 [106]. In ESCC, HNRNPA2B1 promoted the proliferation of ESCC cells through binding to a m 6 A-modified miR-17-92 cluster and upregulating the expression of a miR-17-92 cluster [79]. m 6 A modification could also be found on lncRNAs, which might be involved in the regulation of gene expression via influencing the interaction of lncRNAs with RNA binding proteins through an "m 6 A switch" mechanism or impacting the interaction between lncRNAs and miRNAs [13,107]. In ESCC, the overexpression of FTO significantly reduced the enrichment of m 6 A at site 2 of the LINC00022 transcript and led to a decrease in the degradation of LINC00022 by YTHDF2 [83]. The study of Wu et al. [81] showed that lncRNA LINC00278 encoded a micropeptide named Yin Yang 1 (YY1)-binding micropeptide (YY1BM), and the binding of YTHDF1 to m 6 A-modified LINC00278 led to an increased translation of YY1BM. LncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) is located at nuclear speckles (NSs). The MALAT1-m 6 A-enriched sequence and the binding of YTHDC1 to the m6A of MALAT1 were necessary for maintaining the composition of NSs and migratory capability of ESCC cells [82]. In addition, as mentioned above, lncRNA could interact with m 6 A readers to regulate the expression of target mRNAs [64,65,68,70].
circRNAs perform different biological functions based on their diverse distribution in cells. Nuclear circRNAs might affect transcription and splicing [108,109]. Cytoplasmic circRNAs might not only absorb miRNAs and alleviate their depression of the target mRNA [110,111] but also might interact with RNA binding proteins and enhance their functional impacts [112,113]. It is worth mentioning that the exon-derived circRNAs might have a protein-encoding ability [114,115]. m 6 A regulators regulated the expression, distribution and function of circRNAs through installing, removing and recognizing m 6 A on circRNAs in all sorts of cancers [112,113,[116][117][118][119]. In gastric cancer and cervical cancer, METTL14 and ALKBH5 acted as a transmethylase of circORC5 and demethyltransferase of circCCDC134, respectively [116,117]. YTHDC1 facilitated m 6 A-modified circMET and circNSUN2 exportation from the nucleus to cytoplasm in NONO-TFE3 fusion renal cell carcinoma and colorectal carcinoma, respectively [112,113]. IGF2BP2 interacted with circN-SUN2 to increase the stability of HMGA2 mRNA and promote the metastasis of colorectal carcinoma [113]. IGF2BP1 promoted the translation of m 6 A-modified circMAP3K4 into circMAP3K4-455aa via recognizing m 6 A modification on circMAP3K4 in hepatocellular carcinoma [118]. Interestingly, m 6 A modification on circALG1 enhanced its ability as competitive endogenous RNA (ceRNA) of miR-342-5p by increasing its binding to miR-342-5p in colorectal cancer [119]. It is a pity that no study has reported how m 6 A modification regulates the expression and function of circRNAs during the development and progression of ESCA until now, which provides a direction for future research in ESCA.

The Role of m 6 A Regulators in Development, Progression, Prognosis and Treatment of ESCA
ESCC and EAC are the main pathological subtypes of ESCA. To date, only two studies have been conducted to investigate the expression of m 6 A regulators and their association with clinicopathological characteristics and prognosis in EAC. In some of the studies, although the histological type of tissue samples employed was not indicated clearly, the cells used for cytology experiments were ESCC cells. Therefore, these studies were described alongside studies about ESCC.

m 6 A Regulators and EAC
Plum et al. [120] examined the expression of IGF2BP3 in 371 EAC samples, including 109 early invasive EAC (pT1a/pT1b) and 262 locally advanced EAC (>pT2), with a higher IGF2BP3 expression in locally advanced EAC. The pT1a and pT1b were used to describe a cancerous lesion restricted to the mucosa and submucosa, respectively. The pT1b was further divided into sm1, sm2 and sm3. The IGF2BP3 expression had an elevated trend with an increase in the invasive depth from pT1a to pT1b (sm3). A high IGF2BP3 expression predicted a shorter survival for early invasive EAC patients. The researchers thought that IGF2BP3 might be useful for therapeutic decisions in early invasive EAC. In addition, Burdelski et al. [121] reported an association of a high IGF2BP3 expression with adverse features such as a high grade and metastatic phenotype in EAC.

The Expression of m 6 A Regulators and their Association with Clinicopathological Characteristic in ESCA
The expression, clinical significance and biological function of m 6

• Erasers
The expression of ALKBH5 was downregulated in ESCA tissues [80,86,122,130,131], which was more frequently observed in advanced ESCC such as T3-T4, N1-N3, clinical stage III-IV and histological grade III tumors [122,130,131]. FTO was reported to be increased in ESCA tissues and cell lines in most studies [73,74,83,132]. Female patients and advanced stage patients had a significantly higher FTO expression than male patients and early stage patients, respectively [83]. On the contrary, Zhang et al. [122] found a lower FTO expression in ESCA tissues.
The expression of m 6 A regulators was dysregulated in ESCA and was associated with a clinicopathological characteristic of ESCA, which implied an important role of m 6 A regulators in the development and progression of ESCA. To date, all studies about METTL3 in ESCA showed an upregulation of METTL3. Therefore, METTL3 expression had the potential as a diagnostic marker for ESCA, with a sensitivity of 75% and specificity of 72.06% [85]. In addition, a high standard uptake value (SUVmax) of 18 F-FDG PET/CT could be used as a non-invasive predictive marker for a high METTL3 expression of ESCA patients [125]. The expression of ALKBH5 was downregulated in ESCA. The difference in sample size and detection methods might contribute to inconsistent results about FTO. The amount of studies on other m 6 A regulators is insufficient to draw a preliminary conclusion. The alteration of the nucleotide sequence and epigenetic modification could both impact the expression of m 6 A regulators. For instance, rs2416282 regulated YTHDC2 expression [133]. KAT2A and SIRT2 activated and inhibited the transcription of METTL3 through increasing and decreasing the H3K27 acetylation level in the METTL3 promoter region, respectively [72]. m 6 A regulators not only regulated the expression of various type of RNAs but also received regulation by non-coding RNAs (Table 2) [66,80,122,129,135,136]. LncRNA EMS sponged miR-758-3p, weakened its repression of WTAP and led to an increased expression of WTAP [129]. Furthermore, external stimulus could change the expression of m 6 A regulators. Specifically, cigarette smoking decreased the methylation of the ALKBH5 promoter, enhanced ALKBH5 expression and affected the progression of male ESCC [81]. • Writers METTL3 could promote the proliferation, migration and invasion of ESCC cells and inhibited ESCC cells' apoptosis in an m 6 A-dependent way [59][60][61]75,76,85,122]. As methyltransferase, METTL3 affected the expression of coding RNA and the biogenesis of mi-croRNA through changing the m 6 A level. In METTL3 knockdown cells, m 6 A peaks in the UTRs of glutaminase 2 (GLS2) and expression of GLS2 were decreased, which suggested that METTL3 could upregulate GLS2 expression through increasing the m 6 A level of GLS2. GLS2 knockdown alleviated the migration and invasion ability of ESCC cells increased by METTL3 overexpression. That is, METTL3 could regulate GLS2 expression in an m 6 Adependent way and GLS2 mediated the effect of METTL3 on the malignant phenotype of ESCC cells [59]. Similarly, METTL3 played a crucial role in ESCC initiation and progression through regulating the expression of NOTCH1 in an m 6 A-dependent manner and activating the Notch signaling pathway [60]. The downregulation of METTL3 decreased the m 6 A level of pri-miR-200-5p, inhibited the binding of DGCR8 with pri-miR-200-5p and reduced the expression of miR-200-5p. The upregulation of miR-200-5p could target and inhibit nuclear factor IC (NFIC), which had been reported to play a suppressive role in the proliferation, metastasis and EMT process of ESCC cells [142]. Therefore, METTL3 influenced the malignancy of ESCC cells through regulating the expression of miR-200-5p and NFIC [75]. Similarly, the overexpression of METTL3 elevated the expression of miR-320b, which inhibited the expression of programmed cell death 4 (PDCD4), and then activated the AKT signaling pathway and led to lymphangiogenesis and the lymphatic metastasis of ESCC [76] (Figure 1).

• Erasers
Whether ALKBH5 promoted or inhibited the progression of ESCA was uncertain. ALKBH5 inhibited the biogenesis of miR-194-2 through decreasing its m 6 A modification, upregulated the expression of RAI1, activated the Hippo signaling pathway and suppressed the growth and motility of ESCC cells in vitro and in vivo [78]. Conversely, Nagaki et al. [62] reported that the depletion of ALKBH5 suppressed the proliferation and migration of ESCC cells. Mechanistically, ALKBH5 knockdown increased the m 6 A modification and stability of CDKN1A mRNA and upregulated the expression of p21, a cell cycle inhibitor. Furthermore, the knockdown of ALKBH5 suppressed tumor growth

• Erasers
Whether ALKBH5 promoted or inhibited the progression of ESCA was uncertain. ALKBH5 inhibited the biogenesis of miR-194-2 through decreasing its m 6 A modification, upregulated the expression of RAI1, activated the Hippo signaling pathway and suppressed the growth and motility of ESCC cells in vitro and in vivo [78]. Conversely, Nagaki et al. [62] reported that the depletion of ALKBH5 suppressed the proliferation and migration of ESCC cells. Mechanistically, ALKBH5 knockdown increased the m 6 A modification and stability of CDKN1A mRNA and upregulated the expression of p21, a cell cycle inhibitor. Furthermore, the knockdown of ALKBH5 suppressed tumor growth in nude mice. Collectively, ALKBH5 downregulated the expression of p21 in an m 6 A-dependent way and facilitated cell cycle progression and the proliferation of ESCC cells in vitro and in vivo. LncRNAs may influence mRNA expression through m 6 A RNA modification [143,144]. Qin et al. [63] reported that cancer susceptibility candidate 15 (CASC15) interacted with FTO, reduced the m 6 A level of single-minded 2 (SIM2) mRNA, decreased SIM2 expression and facilitated ESCC progression ( Figure 2). • Readers IGF2BP2 could increase the stability of mRNA individually [66] or in combination with lncRNA [64,65]. LncRNA colon-cancer-associated transcript 2 (CCAT2) absorbed miR-200b, weakened the inhibition of miR-200b on IGF2BP2 and upregulated the expression of IGF2BP2. The overexpression of IGF2BP2 enhanced the expression of TK1 by recognizing the m 6 A of TK1 mRNA, which promoted the oncogenesis of ESCC cells in nude mice and facilitated the migration and invasion of ESCC cells [66]. The interaction of IGF2BP2 with lncRNA small nucleolar RNA host gene 12 (SNHG12) and the interaction of IGF2BP2 with lncRNA forkhead box P4 antisense RNA 1 (FOXP4-AS1) could enhance the mRNA stability of CTNNB1 and forkhead box P4 (FOXP4), respectively, and partly contributed to the proliferation, migration, EMT and stemness of ESCC cells [64,65].
HNRNPA2B1 could increase the expression of the miR-17-92 cluster in an m 6 A-dependent manner, promote the proliferation of ESCC cells and affect the prognosis of ESCA patients negatively [79]. Similarly, HNRNPA2B1 might also facilitate ESCC progression by accelerating fatty acid synthesis via increasing the expression of ACLY and ACC1 [84]. LBX2-AS1 played a critical role in promoting the migration and EMT of ESCC cells, and this role was mediated by HNRNPC through increasing ZEB1 and ZEB2 mRNA stability [68] (Figure 3). • Readers IGF2BP2 could increase the stability of mRNA individually [66] or in combination with lncRNA [64,65]. LncRNA colon-cancer-associated transcript 2 (CCAT2) absorbed miR-200b, weakened the inhibition of miR-200b on IGF2BP2 and upregulated the expression of IGF2BP2. The overexpression of IGF2BP2 enhanced the expression of TK1 by recognizing the m 6 A of TK1 mRNA, which promoted the oncogenesis of ESCC cells in nude mice and facilitated the migration and invasion of ESCC cells [66]. The interaction of IGF2BP2 with lncRNA small nucleolar RNA host gene 12 (SNHG12) and the interaction of IGF2BP2 with lncRNA forkhead box P4 antisense RNA 1 (FOXP4-AS1) could enhance the mRNA stability of CTNNB1 and forkhead box P4 (FOXP4), respectively, and partly contributed to the proliferation, migration, EMT and stemness of ESCC cells [64,65].
HNRNPA2B1 could increase the expression of the miR-17-92 cluster in an m 6 Adependent manner, promote the proliferation of ESCC cells and affect the prognosis of ESCA patients negatively [79]. Similarly, HNRNPA2B1 might also facilitate ESCC progression by accelerating fatty acid synthesis via increasing the expression of ACLY and ACC1 [84]. LBX2-AS1 played a critical role in promoting the migration and EMT of ESCC cells, and this role was mediated by HNRNPC through increasing ZEB1 and ZEB2 mRNA stability [68] (Figure 3). METTL3 was also involved in the progression of ESCC in an m 6 A-independent way [124,126,127]. For example, METTL3 might influence the biological behavior of ESCC cells by regulating Wnt/β-catenin and AKT signaling pathways [124]. In addition, METTL3 facilitated the malignant phenotype of ESCC cells by upregulating the expression of COL12A1 and activating the MAPK signaling pathway [127] (Figure 4). METTL3 was also involved in the progression of ESCC in an m 6 A-independent way [124,126,127]. For example, METTL3 might influence the biological behavior of ESCC cells by regulating Wnt/β-catenin and AKT signaling pathways [124]. In addition, METTL3 facilitated the malignant phenotype of ESCC cells by upregulating the expression of COL12A1 and activating the MAPK signaling pathway [127] (Figure 4).

• Erasers
The overexpression of ALKBH5 induced the apoptosis of ESCC cells by changing the expression of Bax, cleaved caspase 3 and Bcl2 in an m 6 A-independent way [86]. FTO promoted the proliferation and migration of ESCC cells by increasing the expression of MMP13 [132] (Figure 5). • Readers The downregulation of YTHDC2 changed the expression of some genes, which were enriched in p53, NF-kappa B and the JAK-STAT signaling pathway. Therefore, the downregulation of YTHDC2 might enhance the growth of ESCC cells through regulating certain pathological signaling pathways [133]. miR-98-5p and miR-454-3p could suppress the biological phenotype of ESCC cells by targeting IGF2BP1 [134,135].

• Erasers
The overexpression of ALKBH5 induced the apoptosis of ESCC cells by changing the expression of Bax, cleaved caspase 3 and Bcl2 in an m 6 A-independent way [86].  • Readers The downregulation of YTHDC2 changed the expression of some genes, which were enriched in p53, NF-kappa B and the JAK-STAT signaling pathway. Therefore, the downregulation of YTHDC2 might enhance the growth of ESCC cells through regulating certain pathological signaling pathways [133]. miR-98-5p and miR-454-3p could suppress the biological phenotype of ESCC cells by targeting IGF2BP1 [134,135].

• Readers
The downregulation of YTHDC2 changed the expression of some genes, which were enriched in p53, NF-kappa B and the JAK-STAT signaling pathway. Therefore, the downregulation of YTHDC2 might enhance the growth of ESCC cells through regulating certain pathological signaling pathways [133]. miR-98-5p and miR-454-3p could suppress the biological phenotype of ESCC cells by targeting IGF2BP1 [134,135].
The downregulation of miR-186 alleviated its inhibition of HNRNPC, upregulated the expression of HNRNPC and facilitated the malignant behavior of ESCC cells [136].
EIF3B cooperated with TEX9 to promote the malignant phenotype of ESCC cells via activating the AKT signaling pathway [141]. EIF3B also promoted ESCC cells' proliferation and invasion and inhibited ESCC cells' apoptosis through activating the β-catenin signaling pathway [137]. The knockdown of EIF3E repressed the proliferation and migration of ESCC cells [138]. EIF3H could stabilize Snail through deubiquitination and could promote the aggressiveness of ESCC cells [139] (Figure 6). The downregulation of miR-186 alleviated its inhibition of HNRNPC, upregulated the expression of HNRNPC and facilitated the malignant behavior of ESCC cells [136].
EIF3B cooperated with TEX9 to promote the malignant phenotype of ESCC cells via activating the AKT signaling pathway [141]. EIF3B also promoted ESCC cells' proliferation and invasion and inhibited ESCC cells' apoptosis through activating the β-catenin signaling pathway [137]. The knockdown of EIF3E repressed the proliferation and migration of ESCC cells [138]. EIF3H could stabilize Snail through deubiquitination and could promote the aggressiveness of ESCC cells [139] (Figure 6).

• Combined Effects of m 6 A Regulators in Progression of ESCA
METTL3 overexpression enhanced the m 6 A level of adenomatous polyposis coli (APC) mRNA in an METTL14-dependent way, elevated the binding of YTHDF2 with APC mRNA and promoted the degradation of APC mRNA. Ultimately, the downregulation of APC enhanced aerobic glycolysis, ESCC cells growth and tumor formation in mice through activating the Wnt/β-catenin signaling pathway [69].
RBM15 interacted with METTL3 in a WTAP-dependent way to deposit m 6 A onto lncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), located at nuclear speckles (NSs). YTHDC1 bound to the m 6 A of MALAT1, which maintained the composition of NSs and increased the migration of ESCC cells [82].
The combined regulation of EGR1 by METTL3 and YTHDF3 enhanced the expression of EGR1, activated the Snail signaling pathway and promoted the invasion and metastasis of ESCC cells [72].
Cigarette smoking and sexual hormones might be associated with different incidence rates of ESCC between men and women [145][146][147][148]. Wu et al. [81] reported whether and how a micropeptide affected the progression of male ESCC. The micropeptide was named Yin Yang 1 (YY1)-binding micropeptide (YY1BM), which was encoded by Y-linked lncRNA LINC00278. Specifically, cigarette smoking decreased the methylation of an ALKBH5 promoter, enhanced ALKBH5 expression, downregulated the m 6 A modification of LINC00278 and binding of YTHDF1 with LINC00278 and led to a translation suppression of YY1BM. The downregulation of YY1BM increased the survival of ESCC cells through a series of cascade reactions. Furthermore, Wu et al. [81] also reported that METTL3, METTL14 and WTAP acted as "writers" for the m 6 A modification of LINC00278 to participate in the development of male ESCC. miR-193a-3p could target ALKBH5 and inhibit the expression of ALKBH5. The knockdown of ALKBH5 increased the m 6 A level of pri-miR-193a-3p and promoted the maturation of pri-miR-193a-3p. Thus, miR-193a-3p and ALKBH5 formed a positive feedback loop, which facilitated the proliferation and metastasis of ESCC cells in vitro and in vivo. The researchers also revealed that METTL3, as a methyltransferase of pri-miR-193a-3p, played an opposite role in the maturation of miR-193a-3p compared to ALKBH5 [80].
The overexpression of FTO promoted the proliferation and cell cycle progression of ESCC cells, which was realized by accelerating the expression of LINC00022 in a YTHDF2dependent pattern and decay of p21 [83].
FTO could promote the proliferation, migration and invasion of ESCC cells by regulating the m 6 A level and expression of ERBB2 and HSD17B11. Interestingly, YTHDF1, as a reader of ERBB2 and HSD17B11, increased the stability of ERBB2 mRNA but decreased the translation efficiency of HSD17B11 mRNA [73,74].
YTHDF1 could recognize, bind and increase the stability of m 6 A-modified HK2 mRNA and upregulate the expression of HK2, which mediated the role of HCP5 in promoting the progression of ESCC. In this process, METTL3 acted as a methyltransferase of HK2 mRNA [71].
Linc01305 interacted with IGF2BP2 and IGF2BP3 to increase the stability of HTR3A mRNA and expression of HTR3A, and consequently promoted the proliferation and migration of ESCC cells [70] (Figure 7).  Thus, miR-193a-3p and ALKBH5 formed a positive feedback loop, which facilitated proliferation and metastasis of ESCC cells in vitro and in vivo; (C) Ref. [69] Overexpression of METTL3 enhanced m 6 A level of adenomatous polyposis coli (APC) mRNA in an METTL14-dependent way, elevated binding of YTHDF2 with APC mRNA and promoted degradation of APC mRNA. Decreased APC expression facilitated proliferation of ESCC cells through activating Wnt/β-catenin signaling pathway; (D) Ref. [70] Linc01305 interacted with IGF2BP2 and IGF2BP3 to increase stability of HTR3A mRNA and expression of HTR3A, then promoted proliferation and migration of ESCC cells; (E) Ref. [82] RBM15 interacted with METTL3 in a WTAP-dependent way to deposit m 6 A onto MALAT1, specifically located at nuclear speckles (NSs), and YTHDC1 could bind to m 6 A of MALAT1, which was important for NSs homeostasis and metastasis of ESCC cells; (F) Ref. [83] Overexpression of FTO significantly reduced the enrichment of m 6 A at site 2 of LINC00022 transcript and led to a decrease in degradation of LINC00022 by YTHDF2. FTO promoted proliferation of ESCC cells by upregulating expression of LINC00022 in a YTHDF2-dependent pattern; (G) Ref. [71] YTHDF1 increased stability of m 6 A-modified HK2 mRNA and upregulated expression of HK2, which mediated the role of HCP5 in promoting progression of ESCC. In this process, METTL3 acted as methyltransferase of HK2 mRNA; (H) Ref. [73] FTO promoted proliferation, migration and invasion of ESCC cells by regulating m 6 A level of ERBB2, in which, YTHDF1, as reader of ERBB2, increased stability of ERBB2 mRNA; (I) Ref. [74] Combined role of FTO and YTHDF1 resulted in upregulation of HSD17B11 and progression of ESCC, in which, reduced m 6 A level of ERBB2 by FTO led to inhibition of YTHDF1-induced decreased translation efficiency of HSD17B11; (J) Ref. [72] Increased m 6 A level of EGR1 mRNA by METTL3 and increased binding of m 6 A-modified EGR1 mRNA with YTDF3 led to upregulation of EGR1, activated Snail signaling pathway and promoted invasion and metastasis of ESCC cells.
Various signaling pathways mediated the regulation of m 6 A regulators on ESCC, consisting of AKT, NF-κB, MAPK, Wnt/β-catenin, etc. Interestingly, the same gene could target different genes or signaling pathways to influence the malignancy of ESCC. For instance, the target genes and signaling pathways of METTL3 included GLS2, NOTCH1, TNFR1, miR-200-5p, miR-320b, miR-99a-5p, Notch pathway, AKT pathway, MAPK pathway, NF-κB pathway and Wnt/β-catenin pathway [59][60][61]75,76,124,126]. Different genes could also regulate the same gene, such as p21, a cell cycle inhibitor, which participated in the regulation process of METTL3, ALKBH5, FTO and YTHDF2 in ESCC [62,83,85]. Different m 6 A-modified genes could play their regulatory role in ESCC through the same pathway, such as the AKT pathway [76,77,124,126,135,141], NF-κB pathway [61,133] and Wnt/β-catenin pathway [64,69,124,134,137]. Therefore, a combined analysis of m 6 A regulators might be beneficial for better understanding their effect and mechanism in ESCA and providing an experimental basis for the drug research of ESCA.

The Role of m 6 A Regulators in Treatment of ESCA
The survival time of ESCA patients has improved dramatically with the improvement in the surgical level and development of drugs. However, the five-year survival rate of ESCA patients remains dismal due to treatment failure resulting from therapeutic resistance. Thus, it is urgent to identify the mechanism responsible for therapeutic resistance and to find new drugs alone or in combination with other therapeutic agents used to improve the prognosis of ESCA patients. Considering the crucial role of m 6 A regulators in the occurrence and progression of ESCA, m 6 A regulators might be promising therapeutic targets. A previous study demonstrated that the depletion of METTL3 enhanced the sensitivity of pancreatic cancer cells to cisplatin and irradiation [149]. Compared to wildtype mice, YTHDF1 -/mice acquired a better therapeutic efficacy of PD-L1 checkpoint blockade, implying the potential of YTHDF1 as a target of antitumor immunotherapy [150]. Similarly, m 6 A regulators played a non-negligible role in the therapeutic resistance of ESCA [67,77,122,129,151].
Platinum-based agents have been widely applied to treat esophageal cancer patients. Platinum treatment resulted in the upregulation of SNHG3. SNHG3 could sponge miR-186-5p, alleviated the inhibition of METTL3 by miR-186-5p, increased the expression of MTLL3 and promoted the growth of ESCC cells in vitro and in vivo. Therefore, targeting SNHG3/miR-186-5p/METTL3 might enhance the platinum efficacy [122]. Hypoxia could induce the expression of some genes associated with resistance to anticancer drugs, then decreased the sensitivity of cells to chemotherapy. Hypoxia induced the expression of lncRNA E2F1 messenger RNA stabilizing factor (EMS), which could sponge miR-758-3p and weaken its repression of WTAP, increased the expression of WTAP and led to resistance of ESCC cells to cisplatin. Therefore, EMS, miR-758-3p and WTAP might be considered as a therapeutic target to enhance cisplatin efficiency [129]. m 6 A regulators were also associated with radioresistance. Cancer stem-like cells (CSCs) have been reported to be associated with the radioresistance of ESCC cells [152]. METTL14 was downregulated in CSCs, which resulted in a decreased expression of miR-99a-5p in an m 6 A-dependent manner. The downregulation of miR-99a-5p led to an increase in the expression of TRIB2. TIRB2 bridged METTL14 to COP1 and one E3 ligase, and resulted in the ubiquitination and degradation of METTL14. Thus, METTL14, miR-99a-5p and TRIB2 formed a positive feedback circuit. TRIB2 could promote CSCs persistence and the radioresistance of ESCC cells through activating the Akt/mTOR/S6K1 signaling pathway [77]. IGF2BP3 enhanced KIF18A mRNA stability, upregulated KIF18A expression and facilitated ESCC cells' proliferation, migration, invasion and radioresistance [67]. The knockdown of IGF2BP3 increased the susceptibility of radioresistant TE-5 and TE-9 cells to radiotherapy [153]. These results suggested that METTL14/miR-99a-5p/TRIB2 axis and IGF2BP3 might be potential targets for improving the sensitivity of ESCC cells to radiotherapy. m 6 A regulators could be used as a treatment target of herbal medicine for esophageal cancer. HNRNPA2B1 codes for two isoforms, HNRNPA2 and HNRNPB1. The crude extract of a South African medicinal plant, Cotyledon orbiculata, reduced colon cancer cells and ESCC cells proliferation and induced their apoptosis through regulating the alternative splicing of HNRNPA2B1 (decreasing the expression of HNRNPB1). A further investigation on HCT116 cells showed that the silencing of HNRNPB1 led to a switch in the splicing of BCL2L1 from a Bcl-xL anti-apoptotic isoform to a Bcl-xS pro-apoptotic isoform and promoted the apoptosis of HCT116 cells. Thus, HNRNPA2B1 might be a potential treatment target of herbal medicine for ESCA. [151].
Elvitegravir, originally developed to treat human immunodeficiency virus (HIV) infection, could repress the invasion and metastasis of ESCC cells by enhancing the proteasomal degradation of METTL3 mediated by STUB1 [72]. If the therapeutic effect of elvitegravir is proven clinically, there will be an additional option for the treatment of ESCA.

The Association between Expression of m 6 A Regulators and Prognosis of ESCA Patients
The association between the expression of m 6 A regulators and prognosis of ESCA patients was shown in Supplementary Table S2. A higher expression or positive expression of METTL3, WTAP, HNRNPA2B1, HNRNPC and EIF3B was associated with a poor prognosis of ESCA patients [59][60][61]69,72,79,123,126,127,129,130,137]. On the contrary, a lower METTL14 expression predicted a poor overall survival (OS) of ESCA patients [77]. There was no relation between the expression of EIF3E and prognosis of ESCA patients [138]. Xu et al. [130] revealed that a low ALKBH5 expression was associated with a poor survival of ESCA patients. Similarly, ESCA patients with a positive ALKBH5 expression showed a longer OS and disease-free survival (DFS) and less recurrence/distant metastasis after surgery than those with a negative ALKBH5 expression [78]. However, a study on 177 patients showed that a higher ALKBH5 expression was related to a lower OS [62]. There were two studies that reported the association of FTO expression with the prognosis of ESCA patients. One showed the relation of a poor OS with a high FTO expression [74]; the other suggested no relation between them [62]. The difference in subjects, sample size and detection methods might partly explain the discrepancy. For patients treated with surgery alone, a high IGF2BP3 expression was associated with a poor OS, disease-specific survival (DSS) and DFS [154]. Takata et al. [140] reported that IGF2BP3-positive patients had a poorer OS and recurrence-free survival (RFS) than IGF2BP3-negative patients.
Present studies on the association between METTL3 expression and the prognosis of ESCA patients reached a consistent conclusion, which was that a "higher METTL3 expression predicted a poor prognosis of ESCA patients". Results about ALKBH5 and FTO were opposite or inconsistent. The number of studies about other m 6 A regulators is limited. Therefore, further studies are needed to comprehensively analyze the relation between the expression of m 6 A regulators and the survival of ESCA patients due to the complexity of the m 6 A regulatory network. Based on information from the public database, some researchers constructed a prognostic signature according to the expression of m 6 A regulators to predict the survival of ESCA patients [79,84,130,136,155,156]. For example, Xu et al. [130] analyzed the RNA sequencing transcriptome data of 13 m 6 A regulators from the TCGA ESCA database, constructed a prognostic signature, which consisted of HNRNPC and ALKBH5, and established a formula to calculate the risk score. According to the risk score, the ESCA patients were divided into a low risk group and high risk group. Compared with the low risk group patients, the patients in the high risk group had a significantly poorer survival. Therefore, the prognostic signature could be used as an independent prognostic marker for ESCA patients.

Conclusions and Perspectives
After transcription, different chemical modifications can occur on cellular RNA, such as N6-methyladenosine (m 6 A), N6,2 -O-dimethyladenosine (m 6 Am), N1-methyla-denosine (m 1 A) and 5-methylcytosine (m 5 C) [157]. Among them, m 6 A is the most abundant RNA modification, and is dynamic and reversible. m 6 A is catalyzed by methyltransferase, then removed by demethylase or recognized by m 6 A RNA binding protein. During the development and progression of ESCA, m 6 A on various types of RNA was involved in all steps of RNA metabolism, post-transcriptionally regulated the expression of the gene and affected the biological behavior of ESCC cells. m 6 A regulators not only regulated the expression of various type of RNAs but also received regulation by genetic variation, epigenetic modification and non-coding RNAs. During the development of ESCA, METTL3 acted as an oncogene. The mRNA expression level of METTL3 might be used for the diagnosis of ESCA with a sensitivity of 75% and specificity of 72.06%. Furthermore, a high SUVmax of 18F-FDG PET/CT could be used as a non-invasive predictive marker for a high METTL3 expression of ESCA patients. m 6 A regulators participated in the progression of ESCA in an m 6 A-dependent or m 6 A-indepent manner. The same m 6 A regulator could target different genes or signaling pathways to influence the malignancy of ESCA. Similarly, different m 6 A-modified genes could play their regulatory role in ESCA through the same gene or signaling pathway. The m 6 A regulators played a key role in the occurrence and progression of ESCA, which suggested that they might serve as potential therapeutic targets for ESCA. At present, chemotherapy and radiotherapy remain the primary treatment for ESCA. Platinum resistance and radioresistance often result in a poor prognosis of ESCA patients. Targeting the SNHG3/miR-186-5p/METTL3 axis and EMS/miR-758-3p/WTAP axis might help to increase the sensitivity of ESCC cells to platinum; the METTL14/miR-99a-5p/TRIB2 axis and IGF2BP3 might be useful targets for decreasing the radioresistance of ESCC cells. In addition, an extract of Cotyledon orbiculata, a South African medicinal plant, exerted an anti-proliferative effect in ESCC cells through possibly regulating the alternative splicing of hnRNPA2B1 [151]. Moreover, elvitegravir could enhance the proteasomal degradation of METTL3 mediated by STUB1 to repress the invasion and metastasis of ESCC cells [72]. A prognostic signature based on m 6 A regulators is helpful for predicting the prognosis of ESCA patients accurately.
Of note, YTHDF1 has been widely reported to promote protein synthesis. However, YTHDF1 decreased the translation efficiency of HSD17B11 mRNA in the progression of ESCC. In addition, whether ALKBH5 and FTO play roles as an oncogene or cancer suppressor gene is inconclusive, which might be associated with a difference in the sample size, detection method and cell lines employed. In future, a combined analysis of m 6 A regulators in a multi-center study with a large sample size and identical detection method might be beneficial for better understanding their effect and mechanism in ESCA and for drawing a consistent and reliable conclusion.
Inflammation is a physiological response of organisms to various injuries, such as an infection of microorganisms, autoimmunity and physical damage. The disequilibrium of pro-inflammatory factors and anti-inflammatory factors will result in a persistent inflammatory state, so-called chronic inflammation, in which, a large number of cytokines arise and facilitate the initiation, promotion, invasion and metastasis of a tumor [158]. Previous studies revealed a close relation between inflammatory esophageal disease and ESCA [159,160]. In particular, in 58 ESCA patients and 10,614 non-ESCA subjects who received endoscopic examination, there was a significantly higher proportion of esophagitis in ESCA patients (89.7%) than in non-ESCA subjects (14.3%) [161]. The association of m 6 A regulators with pro-inflammatory genes in tumor development and progression has been widely reported. YTHDF2 deletion aggravated the inflammation, angiogenesis and metastatic progression of hepatocellular carcinoma [55]. In another study on intrahepatic cholangiocarcinoma, FTO changed the expression of inflammatory genes via upregulating NR5A2 [162]. In ESCA, there is no similar report. Identifying the target of m 6 A regulators during the process from chronic esophagitis to ESCA would help to determine the pathogenesis of ESCA and provide experimental evidence for the development of a new drug.
To meet the needs of uncontrolled proliferation, one hallmark of cancer, cancer cells must acquire sufficient nutrients from the surrounding tumor microenvironment through regulating various metabolism-associated enzymes, signaling pathways and transcription factors [163]. This ability of cancer cells is termed metabolic reprogramming, which includes the metabolic recombination of glucose, lipid and glutamine; for instance, whether under aerobic conditions or under anoxic conditions cancer cells depend on glycolysis to obtain energy preferentially, which is also known as the "Warburg effect" [164,165]. Glucose transporter 1 (GLUT1) and hexokinase 2 (HK2) are rate-limiting enzymes of the "Warburg effect", responsible for glucose transport and transformation, respectively. Based on multiple public databases, some studies showed a relation between the expression of these two enzymes and m 6 A regulators, which hinted that m 6 A-modified genes participated in glucose metabolic reprogramming [66,125,166], which was validated in some cytological experiments [69,71]. Pyruvate kinase M2 isozyme (PKM2), as a downstream gene of APC regulated by METTl3, METTL14 and YTHDF2, enhanced aerobic glycolysis and, in turn, promoted the proliferation of ESCC cells [69]. The combined effect of METTL3 and YTHDF1, as a writer of HK2 mRNA and reader of m 6 A-modified HK2 mRNA, respectively, caused an upregulation of HK2 and promoted the glycolysis of ESCC cells [71]. m 6 A regulators were also involved in lipid metabolic reprogramming [74,84]. The knockdown of HNRNPA2B1 inhibited the malignant biological behavior of ESCC cells by downregulating the expression of de novo fatty acid synthetic enzymes and suppressing lipid accumulation in ESCC cells [84]. FTO facilitated the growth and invasion of ESCC cells by enhancing the formation of lipid droplets via the regulation of HSD17B11 expression in ESCC cells [74]. So far, whether m 6 A regulators affect glutamine metabolic reprogramming in ESCA has not been disclosed. Targeting metabolism-associated m 6 A regulators might be new strategies for the treatment of ESCA. As shown in one study, some drugs targeting glutaminase isoenzymes had an anticancer effect [167]. Determining the role of m 6 A regulators in ESCA metabolic reprogramming will be beneficial for the development of a new drug.
Immune escape is one of the basic characteristics of tumor cells. The application of immune checkpoint inhibitors (ICIs) that activate antitumor immune cells has shown a significant therapeutic effect on various malignant tumors, including ESCA [168]. However, only a few patients benefit from ICIs treatment because of resistance, thus limiting its application. The tumor-immune microenvironment (TIME), consisting of PD-L1 expression on tumors, tumor-infiltrating lymphocytes, tumor-associated macrophages, etc., might impact the patients' response to ICIs. m 6 A modification is involved in remodeling TIME through regulating the expression of PD-L1 on tumors and regulating the differentiation and activation of tumor-associated immune cells [169][170][171][172][173]. The continual expression of PD-L1 in tumor cells facilitates tumor immune escape. IGF2BP1 recognized PD-L1 mRNA modified by METTL3 and enhanced the expression of PD-L1 in bladder cancer cells, which decreased the attack of CD8 + T cells [170]. The deletion of METTL3 disturbed T cells differentiation and macrophage activation via regulating different downstream target genes [172,173]. In addition, a change in the expression of m 6 A regulators also might influence the distribution and function of immune cells in TIME [174][175][176]. In hepatocellular carcinoma, ALKBH5 promoted macrophage recruitment through upregulating MAP3K8 expression in an m 6 A-dependent manner [174]. In ESCA, some studies revealed that the expression of m 6 A regulators was associated with PD-L1 expression and immune cells infiltration, suggesting the role of m 6 A regulators as an immune therapy target individually or in combination with ICIs [128,155,156,177]. However, how m 6 A regulators affect the TIME of ESCA has not been reported, which provides a direction for future research in ESCA.
In summary, determining the role and mechanism of m 6 A modification and m 6 A regulators in the occurrence, progression, remedy and prognosis of ESCA is necessary for an early diagnosis, individualized treatment and improved prognosis of ESCA patients. Identifying the target of m 6 A regulators during the process from chronic esophagitis to ESCA, the role of m 6 A regulators in metabolic reprogramming and the impact of m 6 A regulators on TIME in ESCA might be a future research direction.
Supplementary Materials: The following supporting information can be downloaded at: https:// www.mdpi.com/article/10.3390/cancers14205139/s1, Table S1: Expression, clinical significance and biological function of m 6 A regulators in ESCA; Table S2: The association between expression of m 6 A regulators and prognosis of ESCA patients.

Conflicts of Interest:
The authors declare no conflict of interest.